Synucleozid-2.0
Based on 1 Customer Validation
Synucleozid-2.0 is a blood-brain barrier-permeable inhibitor that binds to the IRE of SNCA mRNA, with a EC50 of 2.9 µM and a Kd value of 1.8 µM. Synucleozid-2.0 selectively binds to and stabilizes the A bulge and adjacent closed base pairs in the 5' UTR IRE of SNCA mRNA, blocks the translation process and reduces intracellular levels of α-synuclein. Synucleozid-2.0 exerts cytoprotective effects against cytotoxicity induced by α-synuclein preformed fibrils. Synucleozid-2.0 is applicable to the research of Parkinson's disease.
For research use only. We do not sell to patients.
- Purity : 98.01%
- CAS No.: 613226-91-8
- Formula: C22H16BrN7OS
- Molecular Weight:506.38
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
In Vitro
Synucleozid-2.0 selectively binds to the A bulge and its closed base pairs of SNCA IRE RNA, with a competitive Kd of 1.8 µM and an EC50 of 2.9 µM in fluorescence-based assays[1].
Synucleozid-2.0 (0.1-2 µM; 48 h) dose-dependently inhibits the translation of α-synuclein in SH-SY5Y cells with an IC50 of approximately 2 µM, but exerts no effect on the translation of ferritin, TfR or APP[1].
Synucleozid-2.0 (0.1-2 µM; 48 h) dose-dependently inhibits the translation driven by the internal ribosome entry site (IRE) of SNCA in HeLa cells in luciferase reporter assays, whereas it has no effect on reporter genes lacking the SNCA 5' UTR[1].
Synucleozid-2.0 (0.5-10 µM; 48 h) exerts dose-dependent cytoprotective effects on SH-SY5Y cells against α-synuclein PFF-induced toxicity, with an EC50 of 13 µM[1].
Synucleozid-2.0 (0.5-10 µM; 48 h) protects SNCA mRNA in SH-SY5Y cells from RNase H cleavage in a dose-dependent manner by binding to the A-bulge region targeted by Gapmer-1, but has no effect on gapmer-mediated cleavage targeting non-overlapping regions[1].
Synucleozid-2.0 (0-20 µM; 16 h) competes with Syn-ChemCLIP for binding to the same site on SNCA mRNA in SH-SY5Y cells[1].
Synucleozid-2.0 inhibits the translation of α-synuclein in SH-SY5Y cells by blocking the formation of preinitiation complex and preventing ribosome loading onto SNCA mRNA[1].
Synucleozid-2.0 (2 µM; 48 h) reduces α-synuclein levels by approximately 50% in both control and SNCA triplication patient-derived human dopaminergic neurons, without altering SNCA mRNA levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human dopaminergic neuroblastoma SH-SY5Y cells
-
Concentration:0, 0.1, 0.5, 2 µM
-
Incubation Time:48 h
-
Result:Dose-dependently inhibited α-synuclein translation with an IC50 of ~2 µM.
Had no effect on protein levels of ferritin, transferrin receptor (TfR), or amyloid precursor protein (APP).
-
Cell Line:SH-SY5Y cells
-
Concentration:0, 0.5, 2, 10 µM
-
Incubation Time:48 h
-
Result:Dose-dependently protected SH-SY5Y cells against PFF-induced toxicity, with significant cytoprotection observed at all tested concentrations.
Showed no toxicity with treatment alone.
Had an EC50 of 13 µM for cytoprotection.
-
Cell Line:human iPSC-derived dopaminergic neurons (healthy control, Parkinson's disease patient with SNCA triplication)
-
Concentration:2 µM
-
Incubation Time:48 h
-
Result:Decreased α-synuclein protein levels by ~50% in both control dopaminergic neurons and patient-derived dopaminergic neurons with elevated α-synuclein levels.
Reduced patient-derived neuron α-synuclein levels to match untreated control neuron levels.
Had no effect on SNCA mRNA levels in these neurons.
Chemical Information
-
CAS No. 613226-91-8
-
Appearance Solid
-
Molecular Weight 506.38
-
Formula C22H16BrN7OS
-
Color White to light yellow
-
SMILES
O=C(NC1=CC2=C(C=C1)C=NN2)CSC3=NN=C(N3C4=CC=C(C=C4)Br)C5=CC=NC=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (197.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9748 mL | 9.8740 mL | 19.7480 mL | 49.3700 mL |
| 5 mM | 0.3950 mL | 1.9748 mL | 3.9496 mL | 9.8740 mL | |
| 10 mM | 0.1975 mL | 0.9874 mL | 1.9748 mL | 4.9370 mL | |
| 15 mM | 0.1317 mL | 0.6583 mL | 1.3165 mL | 3.2913 mL | |
| 20 mM | 0.0987 mL | 0.4937 mL | 0.9874 mL | 2.4685 mL | |
| 25 mM | 0.0790 mL | 0.3950 mL | 0.7899 mL | 1.9748 mL | |
| 30 mM | 0.0658 mL | 0.3291 mL | 0.6583 mL | 1.6457 mL | |
| 40 mM | 0.0494 mL | 0.2469 mL | 0.4937 mL | 1.2343 mL | |
| 50 mM | 0.0395 mL | 0.1975 mL | 0.3950 mL | 0.9874 mL | |
| 60 mM | 0.0329 mL | 0.1646 mL | 0.3291 mL | 0.8228 mL | |
| 80 mM | 0.0247 mL | 0.1234 mL | 0.2469 mL | 0.6171 mL | |
| 100 mM | 0.0197 mL | 0.0987 mL | 0.1975 mL | 0.4937 mL |